Endometrial Cancer

>

Latest News

Risk factors and biomarker testing in conjunction with cancer staging may better identify ideal treatment for endometrial cancer than cancer staging alone.
Exploring Treatment Options Through Genomic Sequencing in Endometrial Cancer

December 2nd 2024

Risk factors and biomarker testing in conjunction with cancer staging may better identify ideal treatment for endometrial cancer than cancer staging alone.

Deep and durable responses were observed with lenvatinib plus pembrolizumab in patients with stage III/IV recurrent endometrial carcinoma.
Lenvatinib Combo Yields Substantial Antitumor Activity in Endometrial Cancer

September 18th 2024

Pembrolizumab Combo Shows DFS Benefit in dMMR Endometrial Cancer Subgroup | Image Credit: © freshidea - stock.adobe.com.
Pembrolizumab Combo Shows DFS Benefit in dMMR Endometrial Cancer Subgroup

September 15th 2024

“The dMMR population, which are patients who have deficiency in their mismatch repair proteins, had the most pronounced impact in PFS, and we’re seeing that trend for prolonged periods of time; we may be curing many of these patients,” said Ritu Salani, MD.
Dostarlimab With Chemo Changes Practice for dMMR Endometrial Cancer

August 20th 2024

Subgroup analysis data from DUO-E support the European approval of durvalumab-based treatment in primary or recurrent endometrial cancer.
Durvalumab Combos Receive EU Approval in pMMR/dMMR Endometrial Cancer

August 14th 2024

More News